December 10, 2014

Gilead faces lawsuit over hepatitis C drug pricing

byThe Associated Press

Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug.

Sovaldi is a highly effective pill treatment for the most common form of hepatitis C without the injections and unpleasant side effects of earlier treatments.

Gilead has been selling a 12-week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. That has raised complaints by insurers, politicians and patient advocates, particularly because millions of Americans could benefit from the drug.

The complaint was filed in . It says Sovaldi's cost prohibits many patients from getting treatment and accuses Gilead of "unjust enrichment" that violates .

The Foster City, California, company could not be reached immediately for a comment Wednesday.

© 2014 The Associated Press. All rights reserved.

Citation: Gilead faces lawsuit over hepatitis C drug pricing (2014, December 10) retrieved 19 April 2024 from https://medicalxpress.com/news/2014-12-gilead-lawsuit-hepatitis-drug-pricing.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Gilead to license generic version of Sovaldi (Update)
 shares

Feedback to editors
Researchers develop a new way to safely boost immune cells to fight cancer

3 hours ago
New compound from blessed thistle may promote functional nerve regeneration

3 hours ago
New research defines specific genomic changes associated with the transmissibility of the mpox virus

3 hours ago
New study confirms community pharmacies can help people quit smoking

3 hours ago
Researchers discover glial hyper-drive for triggering epileptic seizures

4 hours ago
Deeper dive into the gut microbiome shows changes linked to body weight

4 hours ago
A new therapeutic target for traumatic brain injury

4 hours ago
Dozens of COVID virus mutations arose in man with longest known case, research finds

4 hours ago
Researchers explore causal machine learning, a new advancement for AI in health care

4 hours ago
Analyzing the progression in retinal thickness could predict cognitive progression in Parkinson's patients

4 hours ago
Load comments (0)